First Horizon Advisors’s Denali Therapeutics DNLI Stock Holding History

First Horizon Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25	Closed	-$339	–	2366
2025 Q1	$339	Hold	25	–	–	﹤0.01%	2257
2024 Q4	$509	Hold	25	–	–	﹤0.01%	2188
2024 Q3	$728	Hold	25	–	–	﹤0.01%	2183
2024 Q2	$580	Hold	25	–	–	﹤0.01%	2187
2024 Q1	$513	Sell	25 -195	-89%	-$3.67K	﹤0.01%	2217
2023 Q4	$4.72K	Hold	220	–	–	﹤0.01%	1815
2023 Q3	$4.54K	Sell	220 -11	-5%	-$279	﹤0.01%	1776
2023 Q2	$6.82K	Hold	231	–	–	﹤0.01%	1693
2023 Q1	$5.32K	Buy	231 +16	+7%	+$440	﹤0.01%	1794
2022 Q4	$5.98K	Hold	215	–	–	﹤0.01%	1755
2022 Q3	$6K	Hold	215	–	–	﹤0.01%	1691
2022 Q2	$6K	Buy	215 +200	+1,333%	+$5.24K	﹤0.01%	1756
2022 Q1	$0	Sell	15 -200	-93%	-$6.88K	﹤0.01%	1850
2021 Q4	$9K	Hold	215	–	–	﹤0.01%	1548
2021 Q3	$10K	Buy	+215	New	+$12.1K	﹤0.01%	1526

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's DNLI Position: Q2 2025 in Review

First Horizon Advisors sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 25 shares — an estimated $339 sold.

First Horizon Advisors first reported a position in DNLI in Q3 2021 and held it in 15 quarters. The position peaked at $10K in Q3 2021. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

First Horizon Advisors reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
First Horizon Advisors sold 25 Denali Therapeutics shares in Q2 2025, an estimated $339.
First Horizon Advisors first reported a position in Denali Therapeutics in Q3 2021 and held it in 15 quarters.
First Horizon Advisors's Denali Therapeutics position peaked at $10K in Q3 2021.
230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.